Suppr超能文献

氯贝丁酯、血清酶与肌肉疼痛。

Clofibrate, serum enzymes, and muscle pain.

作者信息

Smith A F, Macfie W G, Oliver M F

出版信息

Br Med J. 1970 Apr 11;2(5701):86-8. doi: 10.1136/bmj.2.5701.86.

Abstract

Serum creatine kinas (C.K.), aspartate amino-transferase (G.O.T.), and alkaline phosphatase (A.P.) activities were measured in 211 men with serum cholesterol concentrations in the upper one-third of the normal distribution. Of these, 110 were receiving clofibrate and 101 were given identical capsules containing olive oil. These investigations were also carried out on 85 healthy men with low serum cholesterol levels not receiving clofibrate.No differences were observed in C.K. and G.O.T. activities between any of these groups; A.P. was significantly lower in the clofibrate-treated group. No significant alterations in C.K. occurred during serial observations made in 15 patients with ischaemic heart disease over a period of five months. No instance of myalgia or muscle stiffness was recorded in 452 men who had received clofibrate for one year.It is concluded that raised C.K. and G.O.T. concentrations and the occurrence of myalgia are uncommon accompaniments of clofibrate treatment.

摘要

对血清胆固醇浓度处于正常分布上三分之一范围的211名男性进行了血清肌酸激酶(C.K.)、天冬氨酸转氨酶(G.O.T.)和碱性磷酸酶(A.P.)活性的测定。其中,110人接受氯贝丁酯治疗,101人服用了含橄榄油的相同胶囊。还对85名未接受氯贝丁酯治疗、血清胆固醇水平较低的健康男性进行了这些研究。这些组之间在C.K.和G.O.T.活性方面未观察到差异;氯贝丁酯治疗组的A.P.显著较低。在对15例缺血性心脏病患者进行的为期五个月的连续观察中,C.K.未出现显著变化。在接受氯贝丁酯治疗一年的452名男性中,未记录到肌痛或肌肉僵硬的病例。结论是,C.K.和G.O.T.浓度升高以及肌痛的发生并非氯贝丁酯治疗的常见伴随情况。

相似文献

1
Clofibrate, serum enzymes, and muscle pain.氯贝丁酯、血清酶与肌肉疼痛。
Br Med J. 1970 Apr 11;2(5701):86-8. doi: 10.1136/bmj.2.5701.86.
3
4
Clofibrate-induced acute muscular syndrome.氯贝丁酯诱发的急性肌肉综合征。
Am J Cardiol. 1972 Oct;30(5):572-4. doi: 10.1016/0002-9149(72)90053-7.
10
No muscle damage from clofibrate.氯贝丁酯未造成肌肉损伤。
N Engl J Med. 1969 Jan 9;280(2):110-1. doi: 10.1056/nejm196901092800221.

引用本文的文献

1
PPARs and pain.过氧化物酶体增殖物激活受体(PPARs)与疼痛。
Br J Pharmacol. 2019 May;176(10):1421-1442. doi: 10.1111/bph.14339. Epub 2018 Jun 3.
2
Combination drug therapy for combined hyperlipidemia.联合高脂血症的联合药物治疗。
Curr Cardiol Rep. 1999 Sep;1(3):244-50. doi: 10.1007/s11886-999-0030-z.
3
[Fat and renal failure--therapeutic aspects].[脂肪与肾衰竭——治疗方面]
Klin Wochenschr. 1982 Aug;60(15):761-6. doi: 10.1007/BF01721140.
5
The effect of lysergic acid di-ethylamide on serum creatine kinase levels.
Psychopharmacologia. 1974;40(2):177-84. doi: 10.1007/BF00421368.
6
Mitochondrial myopathy--a result of clofibrate/etofibrate treatment? Case report.
Acta Neuropathol. 1985;68(2):164-8. doi: 10.1007/BF00688640.
7
Adverse effects of hypolipidaemic drugs.降血脂药物的不良反应。
Med Toxicol. 1987 Jan-Feb;2(1):10-32. doi: 10.1007/BF03259858.
8
Clofibrate-induced myopathy in the rat.
Acta Neuropathol. 1977 Aug 16;39(2):135-8. doi: 10.1007/BF00703319.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验